# Correction to: Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor/Tezacaftor/Ivacaftor treatment

**Authors:** Francesca Buniotto, Gloria Tridello, Antonella De Scolari, Ilaria Meneghelli, Emily Pintani, Sandra Perobelli, Marco Cipolli

PMC · DOI: 10.1186/s41687-025-00976-0 · Journal of Patient-Reported Outcomes · 2026-02-13

## Full-text entities

- **Diseases:** cystic fibrosis (MESH:D003550)
- **Chemicals:** Elexacaftor (MESH:C000629074), Tezacaftor (MESH:C000625213), Ivacaftor (MESH:C545203)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12905042/full.md

---
Source: https://tomesphere.com/paper/PMC12905042